首页> 外文期刊>Journal of cardiovascular pharmacology and therapeutics >Treatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortas
【24h】

Treatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortas

机译:小剂量阿托伐他汀,氯沙坦及其组合治疗可增加大鼠主动脉中血管活性相关基因的表达

获取原文
获取原文并翻译 | 示例
           

摘要

Recently it has been shown that statins and angiotensin receptor blockers (ARBs) at low doses express beneficial pleiotropic vascular effects. We aimed to explore whether these drugs at low doses induce the expression of vasoactive-related genes. Sixty adult Wistar rats were treated with low-dose atorvastatin (2 mg/kg), low-dose losartan (5 mg/kg), their combination or saline daily for 4, 6, or 8 weeks. Expression of the vasoactive-related genes endothelin receptor type A (EDNRA), endothelial nitric oxide synthase 3 (NOS3), inducible nitric oxide synthase 2 (NOS2), and angiotensin II receptor type 1 (AGTRL1a) was measured in isolated thoracic aortas. Expression of EDNRA gradually decreased, the lowest values being obtained after 8 weeks (low-dose atorvastatin, losartan [1.6- and 1-7-fold vs controls, respectively; both P <.05], and the combination [2.3-fold vs control, P <.001]). The highest values of NOS3 were obtained after 6 weeks (low-dose atorvastatin, losartan, and their combination, 3.1-fold, P <.01; 3.4-fold, P <.001; and 3.6-fold, P <.001 vs controls, respectively) and then declined after 8 weeks. The combination was more effective in inducing total NOS3 expression when compared to the separate drugs (1.4-fold; P <.05). Importantly, expression of NOS3 was associated with increased plasma NO levels and positively correlated with thoracic aorta relaxation. No changes in expression of NOS2 and AGTRL1a were observed. We showed that low-dose atorvastatin or losartan and especially their combination increases the expression of NOS3 and decreases the expression of EDNRA. These findings are valuable in explaining the effectiveness of the "low-dose pharmacological approach" for improvement in arterial function.
机译:最近已经显示,低剂量的他汀类药物和血管紧张素受体阻滞剂(ARB)表现出有益的多效性血管作用。我们旨在探讨这些低剂量药物是否诱导血管活性相关基因的表达。每天用低剂量阿托伐他汀(2 mg / kg),低剂量洛沙坦(5 mg / kg),它们的组合或生理盐水治疗60只成年Wistar大鼠,持续4、6或8周。在分离的胸主动脉中测量了血管活性相关基因A的内皮素受体A(EDNRA),内皮型一氧化氮合酶3(NOS3),诱导型一氧化氮合酶2(NOS2)和血管紧张素II受体1型(AGTRL1a)的表达。 EDNRA的表达逐渐降低,在8周后获得最低值(小剂量阿托伐他汀,氯沙坦[分别为对照的1.6倍和1-7倍;两者均P <.05]和组合[2.3倍vs控制,P <.001])。 6周后获得最高NOS3值(低剂量阿托伐他汀,氯沙坦及其组合,分别为3.1倍,P <.01; 3.4倍,P <.001;和3.6倍,P <.001 vs对照),然后在8周后下降。与单独的药物相比,该组合在诱导总NOS3表达上更有效(1.4倍; P <.05)。重要的是,NOS3的表达与血浆NO水平升高有关,并且与胸主动脉舒张正相关。没有观察到NOS2和AGTRL1a表达的变化。我们发现低剂量的阿托伐他汀或氯沙坦,特别是它们的组合增加了NOS3的表达并降低了EDNRA的表达。这些发现对于解释“低剂量药理学方法”对改善动脉功能的有效性是有价值的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号